Randomized trials of cranial radiation therapy plus radiosensitizer in patients with brain metastases
| Study | Year | No. patients | RE | Gy/no. fractions | Median survival time (mo), WBRT + RE vs WBRT |
|---|---|---|---|---|---|
| DeAngelis et al. (19) | 1989 | 58 | Lonidamine | 30/10 | 3.9 vs 5.4 |
| Eyre et al. (61) | 1984 | 111 | Metronidazole | 30/10 | 3.0 vs 3.5 |
| Komarnicky et al. (62) | 1991 | 779 | Misonidazole | 30/6-10 | 3.9 |
| Phillips et al. (63) | 1995 | 72 | BrdUrd | 37.5/15 | 4.3 vs 6.1 |
| Mehta et al. (39) | 2003 | 401 | MGd | 30/20 | 5.2 vs 4.9 |
| 251 NSCLC | Not reached vs 7.4* | ||||
| Suh (64) | 2004 | 5-38 | Efaproxiral | 30/10 | 5.4 vs 4.4 |
| Stea et al. (65) | 2004 | 107 BCA | 4.5 vs 8.6* | ||
| Shaw et al. (66) | 2003 | 57 | Efaproxiral | 30/10 | 6.4 vs 4.1* |
Abbreviations: RE, radioenhancer; BrdUrd, bromodeoxyuridine; MGd, motexafin gadolinium; NSCLC, non–small cell lung cancer; BCA, breast cancer.
↵* P < 0.05.